Rapid, adaptive radiotherapy treatment plans hold potential to reduce toxicity and improve patient outcomes
HAYWARD, Calif., July 7, 2022
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, today announced a non-exclusive, worldwide licensing agreement with Mirada Medical. The agreement allows for the integration of Mirada’s RegEngineÔ image registration algorithms into the RefleXionÒ X1 treatment planning software. The algorithms align patient anatomy between different imaging modalities or between radiotherapy treatments.
“Day-of-treatment modifications, called adaptive radiotherapy, are critical for responding to
changes in patient anatomy that occur as a result of cancer treatment, and to lowering toxicity to improve outcomes,” said Thorsten Melcher, Ph.D., chief business officer at RefleXion. “In challenging patients, such as those with metastatic disease where more than one tumor may be treated, adaptation requires robust tools such as Mirada’s sophisticated RegEngine software, so that clinicians can quickly assess patient anatomy and, in the future their biology, to implement changes to the treatment plan.
“Mirada’s extensive industry experience and development expertise were key factors in our
decision to pursue this agreement,” continued Melcher.
Image registration is a complex series of algorithms that align the images of a patient’s anatomy taken at different points in time and using different imaging modalities. For radiation oncology, where millimeters matter in order to preserve healthy tissue, registration of the tumor target to be treated, as well as nearby anatomy to avoid, is critical. Precise targeting may also result in lowering toxicity, thereby improving outcomes for patients.
BgRT is designed to one day overcome the technical limitations of existing radiotherapy approaches by using a PET radiotracer to create a unified motion management solution for one or multiple tumors. As the PET tracer binds to tumor cells, it produces emissions that signal the cancer’s location. BgRT uses this real-time biological information to deliver a tracked radiation dose to the cancer. Integrating RegEngine into BgRT will allow clinicians to rapidly adapt the daily treatment plan by precisely registering images and image components crucial for treatment planning and dose calculation.
A difficult challenge occurs when the frames of reference of the images are similar, but the patient’s anatomy has changed from biological processes, such as breathing or digestion, or changes in position during the imaging procedures. To assist clinicians in accounting for these changes, RegEngine “warps” or “deforms” the images pixel by pixel, a process called deformable image registration.
“Our relationship with RefleXion is another example of our ability to work with cutting edge oncology companies,” said Jon DeVries, CEO at Mirada. “RefleXion’s biology-guided radiotherapy has the potential to offer a new treatment option for patients with all stages of cancer, and we are excited and proud to have RegEngine selected as a key component of the treatment planning process in this exciting novel technology.”
About Mirada Medical Mirada Medical specializes in simplifying technically complex image processing tasks, allowing clinicians to diagnose disease, assess response to treatment, and plan radiation therapy or surgical intervention more confidently. Mirada launched the first commercial software application to register positron emission tomography (PET) and computed tomography (CT) images in 1999 and has since developed into a world leader in image registration.
About RefleXion Medical RefleXion is a privately-held company developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. *The RefleXion X1 is cleared for SBRT/SRS/IMRT. BgRT is pending regulatory review and is not commercially available.
# # #
RefleXion Amy Cook firstname.lastname@example.org 925-200-212